feedback

Course Director

Mikhail Kosiborod, MD, FACC, FAHA
Mikhail Kosiborod, MD, FACC, FAHA

Vice President for Research, Saint Luke’s Health System
Co-Director, Haverty Cardiometabolic Center of Excellence
Director, Cardiometabolic Research Program, Saint Luke’s Mid America Heart Institute
Professor of Medicine, University of Missouri
Kansas City, Missouri

Faculty

John E. Anderson
John E. Anderson, MD

Past President
The Frist Clinic
Nashville, Tennessee

Silvio E. Inzucchi
Silvio E. Inzucchi, MD

Professor of Medicine
Clinical Chief, Endocrinology
Yale School of Medicine
Medical Director, Yale Diabetes Center
Yale-New Haven Hospital
New Haven, Connecticut

Muthiah Vaduganathan
Muthiah Vaduganathan, MD, MPH

Instructor of Medicine
Brigham and Women’s Hospital
Harvard Medical School
Boston, Massachusetts

Accredited by

Penn State College of Medicine

Activity Description and Educational Objectives

This PeerView onDemand activity, based on an educational session from the 2019 Scientific Sessions of the American Heart Association in Philadelphia, Pennsylvania, features a panel of cardiology, endocrinology, and primary care experts, who provide their clinical perspectives on assessing patients with type 2 diabetes mellitus (T2DM) who are at high risk for cardiovascular (CV) disease and other risk factors. These experts discuss recent and emerging data for antihyperglycemic agents (ie, GLP-1 receptor agonists and SGLT2 inhibitors) and how to incorporate this practice-changing information into individualized treatment plans for these high-risk patients.

Upon completion of this activity, participants should be better able to:
  • Screen patients with or at high risk of CV disease for T2DM
  • Assess individual patients with T2DM for risk factors that frequently complicate diabetes management (ie, history of atherosclerotic CV disease, heart failure, chronic kidney disease, hypoglycemia, obesity)
  • Design individualized treatment regimens that consider and incorporate recent and emerging data for antihyperglycemic agents that have been shown to reduce CV risk in patients with T2DM
  • Collaborate with multidisciplinary colleagues to successfully reduce CV risk in individual patients with T2DM

Target Audience

This activity has been designed to meet the educational needs of clinicians involved in the management of patients with T2DM, including cardiologists, endocrinologists, internists, and primary care physicians.

Requirements for Successful Completion

In order to receive credit, participants must view the activity and complete the post-test and evaluation form. There are no pre-requisites and there is no fee to participate in this activity or to receive CME credit. Statements of Credit are awarded upon successful completion of the post-test and evaluation form.

Media: Enduring Material
Release and Expiration Dates: December 19, 2019 - December 18, 2020
Time to Complete: 90 minutes

Faculty and Disclosure / Conflict of Interest Policy

In accordance with ACCME requirements, Penn State College of Medicine has a conflict of interest policy that requires faculty to disclose relevant financial relationships related to the content of their presentations/materials. Any potential conflicts are resolved so that presentations are evidence-based and scientifically balanced.

Chair

Mikhail Kosiborod, MD, FACC, FAHA
Vice President for Research, Saint Luke’s Health System
Co-Director, Haverty Cardiometabolic Center of Excellence
Director, Cardiometabolic Research Program, Saint Luke’s Mid America Heart Institute
Professor of Medicine, University of Missouri
Kansas City, Missouri

Mikhail Kosiborod, MD, FACC, FAHA, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for Amarin Corporation; Amgen Inc.; Applied Therapeutics; AstraZeneca; Bayer Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; Eisai Inc.; GlaxoSmithKline; Glytec, LLC; Intarcia Therapeutics, Inc.; Janssen Pharmaceuticals, Inc.; Merck & Co., Inc.; Novartis Pharmaceuticals Corporation; Novo Nordisk A/S; and sanofi-aventis U.S. LLC.
Grant/Research Support from AstraZeneca and Boehringer Ingelheim Pharmaceuticals, Inc.

Faculty

John E. Anderson, MD
Past President
The Frist Clinic
Nashville, Tennessee

John E. Anderson, MD, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for Abbott Diabetes; AstraZeneca; Boehringer Ingelheim Pharmaceuticals, Inc.; Eli Lilly and Company; Janssen Pharmaceuticals, Inc.; MannKind Corporation; Merck & Co., Inc.; Novo Nordisk; and Sanofi US.
Speakers Bureau participant with AstraZeneca; Eli Lilly and Company; Janssen Pharmaceuticals, Inc.; Novo Nordisk; and Sanofi US.

Silvio E. Inzucchi, MD
Professor of Medicine
Clinical Chief, Endocrinology
Yale School of Medicine
Medical Director, Yale Diabetes Center
Yale-New Haven Hospital
New Haven, Connecticut

Silvio E. Inzucchi, MD, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for Abbott/Alere; Merck & Co., Inc.; vTv Therapeutics; and Zafgen.
Other financial interest/relationship AstraZeneca, Boehringer Ingelheim Pharmaceuticals, Inc.; Eisai (TIMI); Novo Nordisk, Inc.; Sanofi/Lexicon Pharmaceuticals for Research Steering Committee Member.

Muthiah Vaduganathan, MD, MPH
Instructor of Medicine
Brigham and Women’s Hospital
Harvard Medical School
Boston, Massachusetts

Muthiah Vaduganathan, MD, MPH, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for Amgen Inc.; AstraZeneca; Baxter; Bayer Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; and Relypsa Inc.

Medical Directors

Angela McIntosh
PVI, PeerView Institute for Medical Education

Angela McIntosh has no financial interests/relationships or affiliations in relation to this activity.

Margery Tamas
PVI, PeerView Institute for Medical Education

Margery Tamas has no financial interests/relationships or affiliations in relation to this activity.

Other PVI staff who may potentially review content for this activity have disclosed no relevant financial relationships.

Penn State College of Medicine staff and faculty involved in the development and review of this activity have disclosed no relevant financial relationships.

Providership, Credit, and Support

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Penn State College of Medicine and PVI, PeerView Institute for Medical Education. Penn State College of Medicine is accredited by the ACCME to provide continuing medical education for physicians.

The Penn State College of Medicine designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Information about CME credit for this activity is available by contacting Penn State at 717-531-6483 or ContinuingEd@hmc.psu.edu. Reference course # G6491-20-T.

Providership


This CME activity is jointly provided by Penn State College of Medicine and PVI, PeerView Institute for Medical Education.

Support

This activity is supported by an independent educational grant from Boehringer Ingelheim Pharmaceuticals, Inc. and Lilly USA, LLC.

Disclosure of Unlabeled Use

The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use.

No endorsement of unapproved products or uses is made or implied by coverage of these products or uses in our reports. No responsibility is taken for errors or omissions in reports. For approved prescribing information, please consult the manufacturer’s product labeling.

About This CME Activity

PVI, PeerView Institute for Medical Education, and Penn State College of Medicine are responsible for the selection of this activity’s topics, the preparation of editorial content, and the distribution of this activity. Our activities may contain references to unapproved products or uses of these products in certain jurisdictions. The preparation of PeerView activities is supported by educational grants subject to written agreements that clearly stipulate and enforce the editorial independence of PVI and Penn State College of Medicine.

The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of PeerView or any of its partners, providers, and/or supporters.

Copyright © 2000-2019, PeerView

Suggest a CME Activity

Please provide below the URL and description of an activity you would like to add to OpenCME. You are welcome to add activities as often as you like. To prevent spam or other abuse, activities are reviewed by our editorial team before appearing on OpenCME.

OpenCME for Publishers

Please use the form below if you would like to offer your website visitors high-quality CME content by adding the OpenCME Widget to one or more of your pages.

Send Email to a Colleague

To share this activity with one or more colleagues, enter their e-mail addresses below. To include a personal message, simply overwrite the suggested text below.

(So your recipient knows it's from you.)
Enter multiple recipients separated by a space.
Optionally, replace/modify in the box above the message that will be sent to your colleague(s) with a link to download this app.